Roche says Phase III IMAgINATION trial shows sefaxersen cuts proteinuria in IgA nephropathy patients

(AWP Alliance News) - Roche reported positive prespecified interim results from its Phase III IMAgINATION trial of investigational IgA nephropathy drug sefaxersen, meeting the study's primary endpoint versus placebo at 37 weeks. The treatment delivered a clinically meaningful reduction in proteinuria, a key marker of kidney damage, with no new safety signals.

Roche said the interim data will be presented at an upcoming medical meeting and shared with health authorities. The trial will continue to assess longer-term kidney function over two years, supporting the group's push to position sefaxersen as a potential new option to slow disease progression.

https://www.businesswire.com/news/home/20260922541505/en/

Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief via Business Wire on September 23, 2026, and is solely responsible for the information contained therein.